223 related articles for article (PubMed ID: 25950952)
1. Identification of variants in primary and recurrent glioblastoma using a cancer-specific gene panel and whole exome sequencing.
Virk SM; Gibson RM; Quinones-Mateu ME; Barnholtz-Sloan JS
PLoS One; 2015; 10(5):e0124178. PubMed ID: 25950952
[TBL] [Abstract][Full Text] [Related]
2. Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study.
Tabone T; Abuhusain HJ; Nowak AK; ; Erber WN; McDonald KL
J Clin Pathol; 2014 Jul; 67(7):550-5. PubMed ID: 24695838
[TBL] [Abstract][Full Text] [Related]
3. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.
Kim H; Zheng S; Amini SS; Virk SM; Mikkelsen T; Brat DJ; Grimsby J; Sougnez C; Muller F; Hu J; Sloan AE; Cohen ML; Van Meir EG; Scarpace L; Laird PW; Weinstein JN; Lander ES; Gabriel S; Getz G; Meyerson M; Chin L; Barnholtz-Sloan JS; Verhaak RG
Genome Res; 2015 Mar; 25(3):316-27. PubMed ID: 25650244
[TBL] [Abstract][Full Text] [Related]
4. Correlation of genetic alterations by whole-exome sequencing with clinical outcomes of glioblastoma patients from the Lebanese population.
Saadeh FS; Morsi RZ; El-Kurdi A; Nemer G; Mahfouz R; Charafeddine M; Khoury J; Najjar MW; Khoueiry P; Assi HI
PLoS One; 2020; 15(11):e0242793. PubMed ID: 33237934
[TBL] [Abstract][Full Text] [Related]
5. New insights into the genetics of glioblastoma multiforme by familial exome sequencing.
Backes C; Harz C; Fischer U; Schmitt J; Ludwig N; Petersen BS; Mueller SC; Kim YJ; Wolf NM; Katus HA; Meder B; Furtwängler R; Franke A; Bohle R; Henn W; Graf N; Keller A; Meese E
Oncotarget; 2015 Mar; 6(8):5918-31. PubMed ID: 25537509
[TBL] [Abstract][Full Text] [Related]
6. Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.
Rosenberg S; Verreault M; Schmitt C; Guegan J; Guehennec J; Levasseur C; Marie Y; Bielle F; Mokhtari K; Hoang-Xuan K; Ligon K; Sanson M; Delattre JY; Idbaih A
Neuro Oncol; 2017 Feb; 19(2):219-228. PubMed ID: 27571888
[TBL] [Abstract][Full Text] [Related]
7. Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling.
Zuckermann M; Hovestadt V; Knobbe-Thomsen CB; Zapatka M; Northcott PA; Schramm K; Belic J; Jones DT; Tschida B; Moriarity B; Largaespada D; Roussel MF; Korshunov A; Reifenberger G; Pfister SM; Lichter P; Kawauchi D; Gronych J
Nat Commun; 2015 Jun; 6():7391. PubMed ID: 26067104
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma.
Diamandis P; Ferrer-Luna R; Huang RY; Folkerth RD; Ligon AH; Wen PY; Beroukhim R; Ligon KL; Ramkissoon SH
Diagn Pathol; 2016 Jan; 11():13. PubMed ID: 26817999
[TBL] [Abstract][Full Text] [Related]
9. Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling.
McNulty SN; Cottrell CE; Vigh-Conrad KA; Carter JH; Heusel JW; Ansstas G; Dahiya S
Hum Pathol; 2019 Apr; 86():170-181. PubMed ID: 30594748
[TBL] [Abstract][Full Text] [Related]
10. Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma.
Mahlokozera T; Vellimana AK; Li T; Mao DD; Zohny ZS; Kim DH; Tran DD; Marcus DS; Fouke SJ; Campian JL; Dunn GP; Miller CA; Kim AH
Neuro Oncol; 2018 Mar; 20(4):472-483. PubMed ID: 29244145
[TBL] [Abstract][Full Text] [Related]
11. Genomic characterization of recurrent high-grade astroblastoma.
Bale TA; Abedalthagafi M; Bi WL; Kang YJ; Merrill P; Dunn IF; Dubuc A; Charbonneau SK; Brown L; Ligon AH; Ramkissoon SH; Ligon KL
Cancer Genet; 2016; 209(7-8):321-30. PubMed ID: 27425854
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study.
Pfaff E; Kessler T; Balasubramanian GP; Berberich A; Schrimpf D; Wick A; Debus J; Unterberg A; Bendszus M; Herold-Mende C; Capper D; Schenkel I; Eisenmenger A; Dettmer S; Brors B; Platten M; Pfister SM; von Deimling A; Jones DTW; Wick W; Sahm F
Neuro Oncol; 2018 May; 20(6):826-837. PubMed ID: 29165638
[TBL] [Abstract][Full Text] [Related]
13. Discovering gene-environment interactions in glioblastoma through a comprehensive data integration bioinformatics method.
Kunkle B; Yoo C; Roy D
Neurotoxicology; 2013 Mar; 35():1-14. PubMed ID: 23261424
[TBL] [Abstract][Full Text] [Related]
14. Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing.
Patil V; Pal J; Somasundaram K
Oncotarget; 2015 Dec; 6(41):43452-71. PubMed ID: 26496030
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
Munoz JL; Rodriguez-Cruz V; Ramkissoon SH; Ligon KL; Greco SJ; Rameshwar P
Oncotarget; 2015 Jan; 6(2):1190-201. PubMed ID: 25595896
[TBL] [Abstract][Full Text] [Related]
16. The Personalisation of Glioblastoma Treatment Using Whole Exome Sequencing: A Pilot Study.
Garrett AM; Lastakchi S; McConville C
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32041307
[TBL] [Abstract][Full Text] [Related]
17. Next-generation whole exome sequencing of glioblastoma with a primitive neuronal component.
Xu G; Zheng H; Li JY
Brain Tumor Pathol; 2019 Jul; 36(3):129-134. PubMed ID: 30715630
[TBL] [Abstract][Full Text] [Related]
18. A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel.
Cimino PJ; Bredemeyer A; Abel HJ; Duncavage EJ
Exp Mol Pathol; 2015 Jun; 98(3):568-73. PubMed ID: 25910966
[TBL] [Abstract][Full Text] [Related]
19. Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma.
Indraccolo S; Lombardi G; Fassan M; Pasqualini L; Giunco S; Marcato R; Gasparini A; Candiotto C; Nalio S; Fiduccia P; Fanelli GN; Pambuku A; Della Puppa A; D'Avella D; Bonaldi L; Gardiman MP; Bertorelle R; De Rossi A; Zagonel V
Clin Cancer Res; 2019 Mar; 25(6):1828-1837. PubMed ID: 30514778
[TBL] [Abstract][Full Text] [Related]
20. Targeted 46-gene and clinical exome sequencing for mutations causing cardiomyopathies.
Waldmüller S; Schroeder C; Sturm M; Scheffold T; Imbrich K; Junker S; Frische C; Hofbeck M; Bauer P; Bonin M; Gawaz M; Gramlich M
Mol Cell Probes; 2015 Oct; 29(5):308-14. PubMed ID: 25979592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
